Trending Topics in Gastroenterology
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
The efficacy of TDF, TAF, TMF, and the TDF-to-TAF switch in treating chronic hepatitis B (CHB) has been extensively studied to identify the most effective regimen for individualized...
The gut mycobiome refers to the fungal community residing within the human gastrointestinal system. While the gut microbiome (bacteria) has been extensively studied, the mycobiome remains underexplored, despite...
The direct bilirubin-to-albumin ratio (DBAR) has emerged as a reliable prognostic marker for assessing 28-day mortality in critically ill patients with cirrhosis, as demonstrated by a study utilizing...
Immune dysfunction and infection risk are critical and interlinked concerns in patients with advanced liver disease, including cirrhosis and acute-on-chronic liver failure (ACLF). The immune system undergoes profound...
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive destruction of bile ducts, leading to cholestasis and liver damage. Ursodeoxycholic acid (UDCA) is the...
Bezafibrate has emerged as a significant therapeutic agent for improving transplant-free survival in patients with primary biliary cholangitis (PBC) when used in combination with ursodeoxycholic acid (UDCA). PBC...
The FITCH trial investigated the efficacy of bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist, in alleviating moderate to severe pruritus in patients with fibrosing cholangiopathies, including primary...
The RESPONSE trial was a pivotal phase 3 study designed to evaluate the efficacy and safety of seladelpar, a selective peroxisome proliferator–activated receptor delta (PPARδ) agonist, in patients...
The ELATIVE trial was a clinical study designed to evaluate the efficacy and safety of elafibranor, a dual PPAR-α/δ agonist, as a potential second-line treatment for primary biliary...
The POISE study is a phase 3 clinical trial designed to evaluate the efficacy and safety of obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, in patients...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.